All
Phase 3 Trial in Prostate Cancer Subset Discontinued Due to Lack of Survival Benefit
January 26th 2023A data monitoring committee recommended to stop the phase 3 trial in metastatic hormone-sensitive prostate cancer due to a lack of progression-free survival and overall survival with combination therapy.
Better Quality of Life Reported with Minimally Invasive Esophageal Cancer Treatment
January 23rd 2023Patients who underwent minimally invasive treatment tended to have better quality-of-life outcomes than those who had a full esophagus removal, though there were risk factors for long-term outcomes that should be considered.
Novel Drug-Chemo Combo May Offer ‘New Standard of Care’ for Certain GI Cancers
January 21st 2023Zolbetuximab plus mFOLFOX6 lengthened the time to progression for patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.